Coronavirus disease (COVID-19) updates

As Novartis continues to closely monitor the coronavirus situation, our primary concern is the health and safety of our associates and patients globally. We will continue to deliver our medicines to patients around the world and we do not anticipate supply chain disruption at this time.
 
Novartis has also put the following measures in place:
 

• We are updating travel advisories in line with warning levels provided by the US Centers for Disease Control and Prevention
• We have issued guidance on how our associates can protect themselves against coronavirus infection, and also updated travel restrictions for non-essential business travel worldwide
• Where required, we have enacted mitigation plans to ensure ongoing drug supply to depots for our clinical studies, and we are working closely with the authorities on dispensing to trial participants

 
In response to an urgent call for research and development on coronavirus, issued by the European Federation of Pharmaceutical Industries and Associations (EFPIA), Novartis has expressed its willingness to contribute to this important effort by making available a set of compounds from our libraries that we consider suitable for in vitro antiviral testing. In addition, we are evaluating our existing products to see if any could be repurposed beyond their approved indications.
 
Our generics business Sandoz has committed to keeping prices stable for a basket of essential medicines that may help in the treatment of coronavirus cases, specifically antivirals to reduce the impact of coronavirus and antibiotics to combat pneumonia. Read the Sandoz media release.
 
Novartis remains responsive to any developments regarding coronavirus and will take all necessary steps to protect its associates and patients as the situation evolves.